NASDAQ:IMDX Oncocyte 3/26/2026 Earnings Report $5.01 +0.05 (+1.01%) Closing price 04:00 PM EasternExtended Trading$4.89 -0.12 (-2.38%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Oncocyte EPS ResultsActual EPS-$0.27Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOncocyte Revenue ResultsActual Revenue$1.14 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOncocyte Announcement DetailsQuarterDate3/26/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesSEC FilingEarnings HistoryCompany Profile Oncocyte Earnings HeadlinesiMDx to Release First Quarter 2026 Results on May 13, 2026May 6 at 4:05 PM | globenewswire.comReal-World Evidence and Industry Momentum Builds for iMDx's Flagship GraftAssure AssayApril 14, 2026 | globenewswire.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 8 at 1:00 AM | Profits Run (Ad)Insight Molecular Diagnostics Inc. (IMDX) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | seekingalpha.comIMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 ResultsMarch 26, 2026 | globenewswire.comiMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare ConferenceMarch 20, 2026 | globenewswire.comSee More Oncocyte Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncocyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncocyte and other key companies, straight to your email. Email Address About OncocyteOncocyte (NASDAQ:IMDX) (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges. Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows. Its offerings are positioned to support physicians by reducing diagnostic uncertainty, guiding the need for invasive procedures, and helping to prioritize patients for additional testing or treatment. The company pursues clinical validation and regulatory review as part of its path to broader commercial adoption. Headquartered in the United States, Oncocyte distributes its tests through clinical laboratory networks and strategic partnerships aimed at reaching physicians and healthcare systems. As a publicly listed company on the NASDAQ (IMDX), it concentrates on advancing its diagnostic pipeline, expanding commercial operations, and engaging with payors and clinical stakeholders to integrate its assays into standard oncology care pathways. Information on individual executives and recent leadership changes should be confirmed from the company’s filings and official communications for the most current details.View Oncocyte ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Rocket Lab Posts Record Q1 Revenue, Raises Q2 GuidanceHims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusAppLovin Pops After Earnings With Growth Catalysts in SightDutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality CheckThe AI Fear Around Datadog Stock May Have Been Completely WrongAmprius Technologies Ups the Voltage on Forward OutlookWhy Lam Research Still Looks Like a Buy After a 300% Rally Upcoming Earnings Constellation Energy (5/11/2026)Barrick Mining (5/11/2026)Petroleo Brasileiro S.A.- Petrobras (5/11/2026)Simon Property Group (5/11/2026)SEA (5/12/2026)Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
